Gene therapy injection aims to tame wet macular degeneration

NCT ID NCT06550011

First seen Feb 15, 2026 · Last updated Apr 29, 2026 · Updated 8 times

Summary

This early-stage trial tests a single injection of ABI-110 gene therapy into the eye for people with wet age-related macular degeneration, including a related condition called polypoidal choroidal vasculopathy. The study involves 18 adults aged 50 to 89 and focuses on safety and whether the treatment can improve or stabilize vision over one year. The therapy works by helping the eye produce a protein that blocks abnormal blood vessel growth, which is the root cause of vision loss in this disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEOVASCULAR (WET) AMD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Bay Area Retina Associates

    Walnut Creek, California, 94598, United States

  • California Retina Consultants

    Bakersfield, California, 93309, United States

  • Retina Consultants of Texas

    The Woodlands, Texas, 77384, United States

  • Retina Consultants of Texas - San Antonio

    San Antonio, Texas, 78240, United States

Conditions

Explore the condition pages connected to this study.